Raymond James Trust N.A. Lowers Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Raymond James Trust N.A. trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 6.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,817 shares of the medical equipment provider’s stock after selling 187 shares during the quarter. Raymond James Trust N.A.’s holdings in Hologic were worth $229,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Hologic during the second quarter worth about $25,000. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the 3rd quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the first quarter worth approximately $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic during the second quarter worth $37,000. Finally, First Horizon Advisors Inc. grew its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Royal Bank of Canada raised their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Leerink Partners dropped their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Performance

Shares of HOLX opened at $79.44 on Friday. The company has a 50-day moving average of $80.28 and a two-hundred day moving average of $78.42. The stock has a market cap of $18.45 billion, a P/E ratio of 23.86, a PEG ratio of 2.51 and a beta of 0.98. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.